Worldwide Male Infertility Industry to 2027 - Players Include Sanofi, Bayer & Endo Pharmaceuticals Among Others
DUBLIN, Nov. 26, 2020 /PRNewswire/ -- The "Male Infertility Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Test; Treatment Type; Distribution Channel; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
According to this report the market is expected to reach US $6,213.96 million by 2027 from US $3,883.82 million in 2019; it is estimated to grow at a CAGR of 6.2% from 2020 to 2027. The report highlights the trends prevailing in the global male infertility market, and the drivers and deterrents pertaining to its growth. The growth of the male infertility market is attributed to the increase in male infertility worldwide and technological advancements. However, high cost of procedures hampers the growth of the market.
The male infertility market, by test, is segmented into DNA fragmentation technique, oxidative stress analysis, computer assisted semen analysis, microscopic examination, sperm agglutination, sperm penetration assay, and others. The DNA fragmentation technique segment held the largest share of the market in 2019, whereas the computer assisted semen analysis segment is anticipated to register the highest CAGR of 7.2% in the market during the forecast period. The growing adoption of advanced and improved assisted reproductive technologies, and rise in infertility ratio among males are among the factors augmenting the growth of the male infertility market for the DNA fragmentation technique. Further the rise in the market for computer-assisted semen analysis can be attributed to the growing emphasis of various manufacturers on offering innovative products. For instance, in June 2017, MICROPTIC collaborated with Embryotools for to develop a sperm analysis system in their lab and conduct training for the operations of the same.
MERCK KGaA, Sanofi, Bayer AG, Endo Pharmaceuticals Inc. SCSA Diagnostics, Inc. Andrology Solutions, Halotech DNA, INTAS PHARMACEUTICALS LTD.Cadila Pharmaceuticals Ltd.; and Vitrolife are among the prominent players operating in the male infertility market. The key companies are focused on organic and inorganic strategies to sustain their position in the market. For instance, in January 2020, Merck KGaA received an approval from the European Commission (EC) for its new GONAL-f (follitropin alfa) 150 IU pen, with A goal to strengthen its fertility-related product portfolio for European countries.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the male infertility market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global male infertility market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Key Topics Covered:
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Male Infertility Market - By Test
1.3.2 Male Infertility Market - By Treatment Type
1.3.3 Male Infertility Market - By Distribution Channel
1.3.4 Male Infertility Market - By End-User
1.3.5 Male Infertility Market - By Geography
2. Male Infertility Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Male Infertility Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia-Pacific - PEST Analysis
4.2.4 Middle East and Africa (MEA) - PEST Analysis
4.2.5 South & Central America - PEST Analysis
4.3 Expert Opinion
5. Male Infertility Market- Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increase in Male Infertility Worldwide
5.1.2 Technological Advancements
5.2 Market Restraint
5.2.1 High Cost of Procedures
5.3 Market Opportunity
5.3.1 Conduction of Awareness Campaigns
5.4 Future Trend
5.4.1 Adoption of Assisted Reproductive Technologies (ART)
5.5 Impact Analysis
6. Male Infertility Market - Global Analysis
6.1 Global Male Infertility Market Revenue Forecast and Analysis
6.2 Global Male Infertility Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Male Infertility Market Analysis - By Test
7.1 Overview
7.2 Male Infertility Market Revenue Share, by Test (2019 and 2027)
7.3 DNA Fragmentation Technique
7.3.1 Overview
7.3.2 DNA Fragmentation Technique: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Oxidative Stress Analysis
7.4.1 Overview
7.4.2 Oxidative Stress Analysis: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Microscopic Examination
7.5.1 Overview
7.5.2 Microscopic Examination: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
7.6 Sperm Agglutination
7.6.1 Overview
7.6.2 Sperm Agglutination: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
7.7 Computer Assisted Semen Analysis
7.7.1 Overview
7.7.2 Computer Assisted Semen Analysis: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
7.8 Sperm Penetration Assay
7.8.1 Overview
7.8.2 Sperm Penetration Assay: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
7.9 Others
7.9.1 Overview
7.9.2 Others: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
8. Male Infertility Market Analysis - By Treatment Type
8.1 Overview
8.2 Male Infertility Market Revenue Share, by Treatment Type (2019 and 2027)
8.3 Assisted Reproductive Technology and Varicocele Surgery
8.3.1 Overview
8.3.2 Assisted Reproductive Technology and Varicocele Surgery: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Medication
8.4.1 Overview
8.4.2 Medication: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
9. Male Infertility Market Analysis - By Distribution Channel
9.1 Overview
9.2 Male Infertility Revenue Share, by Distribution Channel (2019 and 2027)
9.3 Hospitals Pharmacies
9.3.1 Overview
9.3.2 Hospitals Pharmacies: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Pharmacies and Drug Stores
9.4.1 Overview
9.4.2 Pharmacies and Drug Stores: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
9.5 Online Pharmacies
9.5.1 Overview
9.5.2 Online pharmacies: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
10. Male Infertility Market Analysis - By End User
10.1 Overview
10.2 Male Infertility Revenue Share, by End User (2019 and 2027)
10.3 Hospitals and Clinics
10.3.1 Overview
10.3.2 Hospitals and Clinics: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
10.4 Fertility Centers
10.4.1 Overview
10.4.2 Fertility Centers: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
10.5 Research Institutes
10.5.1 Overview
10.5.2 Research Institutes: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
10.6 Others
10.6.1 Overview
10.6.2 Others: Male Infertility Market - Revenue and Forecast to 2027 (US$ Million)
11. Male Infertility Market - Geographic Analysis
11.1 North America: Male Infertility Market
11.2 Europe: Male Infertility Market
11.3 Asia Pacific: Male Infertility Market
11.4 Middle East and Africa: Male Infertility Market
11.5 South and Central America: Male Infertility Market
12. Impact of COVID-19 Pandemic on Global Male Infertility Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
12.4 Rest of the World: Impact Assessment of COVID-19 Pandemic
13. Male Infertility Market- Industry Landscape
13.1 Overview
13.2 Strategic Developments
14. Company Profiles
14.1 MERCK KGaA
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Sanofi
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Bayer AG
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Endo Pharmaceuticals Inc.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 SCSA Diagnostics, Inc.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Andrology Solutions
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Halotech DNA
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 INTAS PHARMACEUTICALS LTD.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Cadila Pharmaceuticals Ltd.
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Vitrolife
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About the Publisher
15.2 Glossary of Terms, Male infertility Market
For more information about this report visit https://www.researchandmarkets.com/r/y00fo7
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article